Weight Loss with Wegovy®

Wegovy® (i.e., semaglutide) for Weight Loss and Metabolic Health

Wegovy® (semaglutide) is a GLP-1 medication used for long-term weight management in appropriate patients with obesity or who are overweight with comorbidities.

Wegovy works by reducing hunger and food intake for substantial weight loss while improving several measures of metabolic health. At Kass Precision Medicine, we consider medication within the larger context of body composition, cardiometabolic health, hormone health, nutrition, exercise, muscle preservation, and long-term weight maintenance.


Schedule a Medical Weight Loss Consultation TODAY

What Is Wegovy?

Wegovy is the brand name for semaglutide, a medication that activates the glucagon-like peptide-1 (GLP-1) receptor. 

GLP-1 is a naturally occurring hormone involved in appetite, satiety, glucose regulation, and digestion. Semaglutide acts on this pathway to reduce hunger and food intake while helping people feel satisfied with less food.

Wegovy is available in injectable and oral formulations.

How Does Wegovy Work?

REDUCES HUNGER SIGNALS
Activates GLP-1 receptors in areas of the brain that regulate appetite and satiety, helping reduce hunger and the drive to eat.

QUIETS “FOOD NOISE”
Reduces food preoccupation and the rewarding pull of food, making it easier for many people to think about food less and consume fewer calories.

INCREASES FULLNESS
Slows gastric emptying, particularly earlier in treatment, and promotes satiety, so smaller amounts of food feel more satisfying.

IMPROVES GLUCOSE REGULATION
Increases glucose-dependent insulin secretion and reduces glucagon when blood glucose is elevated, helping improve glucose control and insulin sensitivity.

REDUCES STORED FAT
By substantially reducing caloric intake over time, Wegovy shifts energy balance toward weight loss, with much of the weight lost coming from fat mass, including abdominal and visceral fat.

How Is Wegovy Different From Zepbound?

Wegovy and Zepbound are both used for medical weight management, but they differ slightly in mechanism, formulation, and they each have their own additional FDA indications outside of weight loss. 

DUAL GIP + GLP-1 ACTION

Zepbound is a dual-peptide medication, and it activates both GIP and GLP-1 receptors.

Wegovy acts on the GLP-1 receptor alone.

SLEEP APNEA TREATMENT

Zepbound is FDA-approved to treat moderate-to-severe obstructive sleep apnea in adults who are obese.

See the detailed Zepbound vs. Wegovy comparison ↓

ZEPBOUND LED TO SLIGHTLY GREATER WEIGHT LOSS COMPARED TO WEGOVY

In the SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight loss than semaglutide over 72 weeks. 

Zepbound (tirzepatide): 20.2% average body-weight reduction

Wegovy (semaglutide): 13.7% average body-weight reduction

Is Wegovy the Same as Ozempic?

Wegovy and Ozempic contain the same active medication - semaglutide - but are simply released under different names for different FDA-approved indications.

Ozempic is primarily used in the treatment of type 2 diabetes, while Wegovy is specifically approved for patients who are obese or overweight with comorbidities. Wegovy also has indications for cardiovascular risk reduction in certain higher-risk patients.

The brand names are therefore not interchangeable, even though the underlying medication is the same.

Is Wegovy the same as semaglutide?

Wegovy is the FDA-approved brand name for semaglutide. Semaglutide is the active medication or ingredient within Wegovy and what affects GLP-1 receptors.

Semaglutide may also be prescribed as a compounded medication in certain circumstances when a clinician determines that a patient has an individualized medical need that cannot be met by the commercially available product. Compounded medications are not FDA-approved and do not undergo the same premarket review as Wegovy.

For some patients, an appropriately prescribed compounded formulation may offer clinically useful flexibility, such as a dosage or formulation tailored to an individual medical need. The decision to use branded Wegovy or a compounded semagutide medication should be made with an experienced clinician and, when compounding is appropriate, and filled by a licensed compounding pharmacy.

How Does Wegovy Work for Weight Loss?

Semaglutide influences several biological processes involved in weight regulation:

  • Reduces hunger and appetite

  • Increases satiety

  • Reduces food intake

  • Slows gastric emptying, particularly earlier in treatment

  • Improves glucose regulation and insulin sensitivity

For many patients, the most noticeable effect is a reduction in persistent hunger or preoccupation with food that can make sustained weight loss difficult.

Medication does not replace nutrition, exercise, or other aspects of metabolic health. It changes some of the biological signals involved in appetite and weight regulation.

How Much Weight Can You Lose With Wegovy?

Individual response varies, but semaglutide has produced substantial weight loss in clinical trials.

In major studies of once-weekly injectable semaglutide in adults without diabetes, average weight loss has been approximately 15% of starting body weight with lifestyle intervention.

Clinical trials of oral semaglutide have also demonstrated substantial weight loss. Because the pivotal oral studies did not directly compare oral and injectable Wegovy, their results should not be interpreted as demonstrating that the two formulations produce equivalent weight loss.

Some people lose considerably more or less than these averages. Treatment response, tolerability, body composition, metabolic health, and the sustainability of the strategy are all important considerations.

Wegovy Pill vs. Injection

Wegovy is available in oral and injectable formulations, providing different options for semaglutide treatment.

Neither formulation is automatically the better choice. Medical history, treatment goals, lifestyle, tolerability, dosing preference, and response can all inform the decision.

ORAL WEGOVY

  • Taken once daily

  • Contains semaglutide

  • Avoids injections

  • Requires specific timing around food, beverages, and other medications for reliable absorption

INJECTABLE WEGOVY

  • Taken once weekly

  • Contains semaglutide

  • Does not require daily medication timing

  • Available in multiple doses to allow gradual titration

Wegovy and Cardiovascular Health

One of the most important findings in semaglutide research is evidence that its benefits can extend beyond weight loss.

In the SELECT cardiovascular-outcomes trial, more than 17,600 adults with established cardiovascular disease and overweight or obesity - but without diabetes - received injectable semaglutide or placebo. Major cardiovascular events occurred in 6.5% of participants receiving semaglutide compared with 8.0% receiving placebo, representing a 20% relative reduction in risk.

Based on these data, Wegovy is FDA-approved to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and overweight or obesity.

This indication applies to a specific higher-risk patient population and should not be generalized to everyone taking Wegovy for weight loss.

Wegovy and Metabolic Health

Weight loss with semaglutide can affect more than body weight.

Reducing excess fat - particularly visceral abdominal fat - can improve insulin sensitivity, glucose regulation, blood pressure, triglycerides, and other cardiometabolic risk factors.

For patients with prediabetes, insulin resistance, metabolic liver disease, or other weight-related metabolic concerns, these changes may be an important part of the rationale for treatment.

Weight Loss Shouldn’t Mean Losing Muscle

Significant weight loss can involve loss of both fat and lean tissue. Preserving skeletal muscle is particularly important in midlife and beyond.

Our approach emphasizes adequate protein intake, resistance training, appropriate nutrition, and thoughtful medication dosing to support muscle preservation while reducing excess fat.

The goal is better body composition - not simply lower body weight.

 How Does Wegovy Affect Women and Men?

Wegovy acts through the same GLP-1 pathway in women and men, but the clinical context can differ.

Wegovy is not a treatment for hormonal deficiency in either women or men. These issues should be evaluated independently when clinically relevant.

WOMEN

Perimenopause and menopause can contribute to increased abdominal fat and loss of lean mass. PCOS, insulin resistance, sleep, and other hormonal or metabolic factors may also influence weight and treatment goals.

MEN

Visceral abdominal fat and age-related loss of muscle are particularly relevant to metabolic health in men. Sleep apnea, insulin resistance, and, when clinically indicated, testosterone deficiency may also warrant evaluation.

What Can I Expect When Taking Wegovy?

The experience varies from person to person.

Many men notice less hunger, earlier fullness, smaller portions, and less interest in food as the dose is gradually increased.

Nausea, diarrhea, constipation, vomiting, abdominal discomfort, or reflux can occur, particularly during dose escalation. Gradual titration and adjustment based on response and tolerability are important.

Wegovy Side Effects and Safety

The most common side effects of Wegovy are gastrointestinal and may include:

  • Nausea

  • Diarrhea

  • Constipation

  • Vomiting

  • Abdominal discomfort

  • Indigestion or reflux

More significant adverse effects can occur and should be reviewed before treatment.

Wegovy carries a boxed warning regarding thyroid C-cell tumors observed in animal studies and should not be used in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Medical history, current medications, pregnancy considerations, gastrointestinal health, and other potential contraindications should be reviewed before starting treatment.

Who Is a Candidate for Wegovy?

Wegovy is approved for long-term weight management in adults with obesity, or adults with overweight plus at least one weight-related health condition, when appropriate.

Eligibility for a medication and the decision to use it are not necessarily the same thing.

We also consider:

  • Metabolic and cardiovascular risk

  • Body composition and visceral fat

  • Prediabetes or insulin resistance

  • Weight history and previous treatment

  • Current medications

  • Medical history and contraindications

  • Treatment goals and patient preference

For some patients, another medication - or a strategy that does not involve medication - may be more appropriate.

What Happens If You Stop Wegovy?

Weight regain after stopping semaglutide is common because the biological signals involved in hunger and weight regulation can return when medication is discontinued.

That does not mean every patient must remain on the same medication or dose indefinitely. Long-term strategies may include continued therapy, individualized dosing, transitioning treatment, or carefully monitored discontinuation.

Planning for maintenance should begin before goal weight is reached.

How We Use Wegovy at Kass Precision Medicine

Wegovy is started at a low dose and increased gradually based on response and tolerability. The goal is not necessarily to reach the highest possible dose. Dosing can be guided by weight trajectory, appetite, metabolic response, side effects, body composition, and overall health goals. Nutrition, protein intake, resistance exercise, sleep, and other relevant metabolic or hormonal factors are addressed alongside medication.

START LOW → TITRATE THOUGHTFULLY → MONITOR RESPONSE → PRESERVE MUSCLE → PLAN FOR MAINTENANCE

Wegovy vs. Zepbound: A Closer Comparison


Active medication

Wegovy®Semaglutide

Zepbound®Tirzepatide


Mechanism

Wegovy®GLP-1

Zepbound®GIP + GLP-1


Formulation

Wegovy®Injection or oral tablet

Zepbound®Once-weekly injection


average weight loss*

Wegovy®13.7%

Zepbound®20.2%


FDA indication

Wegovy®Cardiovascular risk reduction in certain adults with established CVD and overweight or obesity

Zepbound®Moderate-to-severe OSA in adults with obesity


*SURMOUNT-5 compared maximum tolerated doses of injectable semaglutide and tirzepatide over 72 weeks in adults with obesity without diabetes. Average trial results do not determine which medication is appropriate for an individual patient. Medical history, treatment goals, cardiovascular and metabolic health, formulation, tolerability, and individual response all matter.

Wegovy at Kass Precision Medicine

Wegovy can be an effective treatment for appropriate patients, but medication is only one component of weight management. Our approach considers body composition, metabolic health, nutrition, exercise, muscle preservation, medication response, and long-term maintenance throughout treatment.

Frequently Asked Questions About Wegovy

Is Wegovy the same as semaglutide?

Wegovy contains semaglutide. Semaglutide is the active medication; Wegovy is one of the brand names under which it is FDA-approved and prescribed.

Is Wegovy the same as Ozempic?

No. Both contain semaglutide, but they have different FDA-approved indications and dosing. Wegovy is specifically approved for chronic weight management in appropriate patients, while Ozempic is primarily used to treat type 2 diabetes.

Does Wegovy come in pill form?

Yes. Wegovy is available in both oral and injectable formulations. The oral formulation provides a non-injectable semaglutide option for weight management.

Does oral Wegovy work as well as the injection?

Oral Wegovy has demonstrated substantial weight loss in clinical trials, but the pivotal oral study did not directly compare oral Wegovy with injectable Wegovy. The available trial results therefore do not establish that the two formulations produce equivalent weight loss.

What is Wegovy HD?

Wegovy HD is a higher-dose 7.2 mg once-weekly semaglutide injection approved by the FDA in March 2026 for weight loss and long-term weight maintenance in certain adults with obesity or overweight plus a weight-related condition. It is not necessarily appropriate - or necessary - for every patient taking Wegovy.

How quickly does Wegovy start working?

Some people notice changes in hunger and satiety relatively early in treatment, but Wegovy is gradually titrated and weight loss typically occurs over many months. Response varies between individuals.

How much weight can I expect to lose with Wegovy?

Clinical trials of injectable semaglutide have generally produced average weight reductions around 15% in adults without diabetes at the traditional 2.4 mg dose, although individual results vary.

Can Wegovy reduce the risk of heart attack or stroke?

Yes, in a specific population. Wegovy is FDA-approved to reduce cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and overweight or obesity. This indication should not be generalized to all patients taking Wegovy for weight loss.

Will I lose muscle on Wegovy?

Some lean tissue can be lost during significant weight loss. Adequate protein, resistance training, appropriate nutrition, and attention to the rate and magnitude of weight loss can help preserve muscle.

Do I have to take Wegovy forever?

Not necessarily, but obesity and weight dysregulation are often chronic. Weight regain after discontinuing semaglutide is common. Decisions about continuing, adjusting, transitioning, or discontinuing treatment should be individualized and accompanied by a long-term maintenance strategy.

Is Wegovy better than Zepbound?

Neither medication is the appropriate choice for every patient. In the SURMOUNT-5 direct comparison, tirzepatide produced greater average weight loss than semaglutide - 20.2% versus 13.7% over 72 weeks - but medication selection also depends on medical history, cardiovascular and metabolic health, formulation, tolerability, treatment goals, and individual response.

Can Wegovy be used during pregnancy?

Wegovy is not used for weight loss during pregnancy. Pregnancy plans should be discussed before treatment because semaglutide needs to be discontinued in advance of a planned pregnancy.

Can Wegovy help with prediabetes or insulin resistance?

Weight loss and semaglutide treatment can improve glucose regulation and insulin sensitivity. For patients with prediabetes or insulin resistance, metabolic response can be monitored alongside weight and body composition.

Schedule a Medical Weight Loss Consultation Today

Read Related Articles From Our Blog